Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 7/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17215507 | 0.94 | LPAR1 (0.39) | LPAR1LPAR3 | |
| SCHEMBL17367447 | 0.94 | LPAR1 (0.33) | LPAR1LPAR3 | |
| SCHEMBL17367460 | 0.93 | LPAR1 (0.35) | LPAR1LPAR3 | |
| SCHEMBL17215294 | 0.91 | OPRM1 (0.34) | LPAR1LPAR3 | |
| SCHEMBL17367421 | 0.90 | LPAR1 (0.39) | LPAR1LPAR3 | |
| SCHEMBL17367426 | 0.89 | LPAR1 (0.37) | LPAR1LPAR3AKR1C3AKR1C2 | |
| SCHEMBL17367427 | 0.88 | LPAR1 (0.37) | LPAR1LPAR3 | |
| SCHEMBL17367444 | 0.88 | LPAR1 (0.35) | LPAR1LPAR3AKR1C3AKR1C2 | |
| SCHEMBL17367422 | 0.88 | LPAR1 (0.38) | LPAR1LPAR3 | |
| SCHEMBL17215481 | 0.88 | LPAR1 (0.39) | LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885LPAR3 1/4885AKR1C3 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.